Drug Trial Radar · NCT05753033
The Pharmacokinetics (PK), Safety, Tolerability of SR750 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Feb 28, 2023
Primary completion
Sep 6, 2023
Study completion Sep 6, 2023
Sponsor
- Lead sponsor
- Shanghai SIMR Biotechnology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled phase I PK bridging study to evaluate the PK, safety and tolerability of SR750 in healthy subjects.
Conditions
- Healthy
Interventions
SR750 tabletDrug
Ascending single and multiple doses of SR750 orally
PlaceboDrug
Ascending single and multiple doses of placebo orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: Up to Day 9
- TmaxTime frame: Up to Day 9
- AUCTime frame: Up to Day 9
- CL/FTime frame: Up to Day 9
- t1/2Time frame: Up to Day 9
- RacTime frame: Up to Day 9
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Clinical Research Center Phase I Clinical Research Unit (SCRC-PCRU)
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.